OBJECTIVES:

: 

The objective of the present study is to perform a cost minimization analysis and budget impact model of including Grazoprevir/Elbasivir in the Mexican National Health System for treating HCV.

METHODS:

: cost minimization analysis and budget impact model was performed with the Mexican National Health System perspective. Based on epidemiological data and scientific publications review, the target population was determined and compared to other therapies (Daclatasvir, Ledipasvir / Sofosbuvir (SOF), Ombitasvir / Paritaprevir / Ritonavir and Simeprevir). A hypothetical population of patients with HCV infection was considered. Clinical and economic parameters of the model were extracted from the literature. Only direct costs were considered. The time horizon was 5 years and a 5% discount rate was applied. All costs are expressed in USD using an exchange rate of 1 MXN= 0.0528128 USD.

RESULTS:: Pharmacological cost of treating 1,172 genotype 1 HCV patients with Grasoprevir/Elbasvir (+/- RBV) is $ 4,873,572.16 USD (Cheapest option) whereas Ombitasvir/Paritaprevir and Ritonavir (+RBV) was $ 15,815,199.85 USD (most expensive option).

The pharmacological cost of treating 11 patients of genotype 4 has the same trend, with Grazoprevir / Elbasvir (+/- RBV) at $ 102,606.60 USD (cheapest option); while if Daclatasvir + SOF (+ RBV) is used, the cost rises to $ 279,409.27 USD (most expensive option).

The use of Grazoprevir / Elbasvir would generate an estimated budget savings of $ 10,104,543.26 distributed over the period 2017-2021. This is a percentage increase from 2.98 to 11.92%. 

CONCLUSIONS:

: The results indicate that the use of Grazoprevir / Elbasvir generates significant savings.